Resistant hypertension-defining the scope of the problem.
Resistant hypertension-defining the scope of the problem.
复制标题
DOI：
10.1016/j.pcad.2019.12.006
复制
发表时间：
2020-01
影响因子：
9.1
通讯作者：
Vongpatanasin W
中科院分区：
文献类型：
--
作者：
Chia R;Pandey A;Vongpatanasin W
美国心脏协会更新的科学声明将顽固性高血压（HTN; RH）定义为不受控制的血压（BP）≥ 130/80 mmHg，尽管同时使用3种抗HTN药物类别，包括钙通道阻滞剂、肾素-血管紧张素系统阻滞剂和噻嗪类利尿剂，优选氯噻酮。使用更新的BP标准，发现美国的RH患病率在治疗人群中适度增加约3-4%。观察性研究的荟萃分析表明，来自白色被毛HTN或药物不依从性的假RH与真正的RH一样常见。因此，在所有明显RH的评估中筛查假耐药是至关重要的，因为白大衣HTN的诊断不需要治疗，而药物不依从性将受益于识别和靶向依从性障碍。
The updated scientific statement by the American Heart Association has defined resistant hypertension (HTN; RH) as uncontrolled blood pressure (BP) ≥ 130/80 mmHg, despite concurrent use of 3 anti-HTN drug classes comprising a calcium channel blocker, a blocker of renin-angiotensin system, and a thiazide diuretic, preferably chlorthalidone. Using the updated BP criteria, the prevalence of RH in the United States is found to be modestly increased by approximately 3–4% among treated population. Meta-analysis of observational studies have demonstrated that pseudo-RH from white coat HTN or medication nonadherence is as much common as the truly RH. Thus, screening for pseudo-resistance in the evaluation of all apparent RH is of utmost importance as diagnosis of white-coat HTN requires no treatment, while medication nonadherence would benefit from identifying and targeting barriers to adherence.
登录
查看更多内容
DOI：
10.1161/hyp.0000000000000084
发表时间：
2018-11
期刊：
Hypertension (Dallas, Tex. : 1979)
影响因子：
--
作者：
Carey RM;Calhoun DA;Bakris GL;Brook RD;Daugherty SL;Dennison-Himmelfarb CR;Egan BM;Flack JM;Gidding SS;Judd E;Lackland DT;Laffer CL;Newton-Cheh C;Smith SM;Taler SJ;Textor SC;Turan TN;White WB;American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council
通讯作者：
American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council
影响因子：
4.2
作者：
Choi SI;Kim SK;Park S;Kim JH;Ihm SH;Kim GI;Kim WS;Pyun WB;Kim YM;Shin J
通讯作者：
Shin J
影响因子：
3.5
作者：
Borghi, Claudio;Tubach, Florence;Halcox, Julian P.
通讯作者：
Halcox, Julian P.
影响因子：
8.3
作者：
Gupta, Pankaj;Patel, Prashanth;Tomaszewski, Maciej
通讯作者：
Tomaszewski, Maciej
影响因子：
24
作者：
De Nicola, Luca;Gabbai, Francis B.;Minutolo, Roberto
通讯作者：
Minutolo, Roberto